3-D Matrix Ltd
TSE:7777
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
3
|
3-D Matrix Ltd
TSE:7777
|
JP |
|
Repsol SA
XETRA:REP
|
ES |
|
Synlait Milk Ltd
NZX:SML
|
NZ |
|
Muromachi Chemicals Inc
TSE:4885
|
JP |
|
I-O Data Device Inc
TSE:6916
|
JP |
|
Smartphoto Group NV
XBRU:SMAR
|
BE |
|
P
|
Pearson PLC
F:PES
|
UK |
|
Beaglee Inc
TSE:3981
|
JP |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
US |
|
P
|
PBS Bhd
KLSE:PBSB
|
MY |
|
EcoPro BM Co Ltd
KOSDAQ:247540
|
KR |
|
AST Groupe SA
PAR:ALAST
|
FR |
|
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
CN |
|
Pioneer Credit Ltd
ASX:PNC
|
AU |
|
Kaonavi Inc
TSE:4435
|
JP |
3-D Matrix Ltd
3-D Matrix Ltd. engages in the research, development, manufacture, and sale of medical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 69 full-time employees. The company went IPO on 2011-10-24. The firm has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
3-D Matrix Ltd. engages in the research, development, manufacture, and sale of medical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 69 full-time employees. The company went IPO on 2011-10-24. The firm has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
